As part of the agreement, Prasco, LLC is prepared to market the authorized generic version of PENTASA® (mesalamine) Controlled-Release Capsules, at Shire's request, immediately upon any entrance into the United States market of an approved ANDA for any generic mesalamine product which is AB-rated to PENTASA®. (At the present time, the FDA has not approved any ANDA for PENTASA®.) The authorized generic will be marketed in the United States in 250 mg and 500 mg strengths under the Prasco label.
"We are excited to have established this new business relationship with Shire," stated Prasco Chief Executive Officer, E. Thomas Arington. "Patients and pharmacists alike benefit when a company such as Shire commits to maintaining the supply of brand-identical medication through the Prasco Authorized Generic business model," Arington concluded.
"We are excited to have established this new business relationship with Shire," stated Prasco Chief Executive Officer, E. Thomas Arington. "Patients and pharmacists alike benefit when a company such as Shire commits to maintaining the supply of brand-identical medication through the Prasco Authorized Generic business model," Arington concluded.
Companies in this press-release
